Celera, Berkeley HeartLab, Ipsogen, DNAVision, Immunicon, Merck Serono, Helixis, Royal Philips Electronics, Gene Logic, Solvay Pharmaceuticals | GenomeWeb
Celera Buys Berkeley HeartLab for $195M to Build CVD Testing Portfolio
 
Celera said this week that it will buy Berkeley HeartLab, a California-based personalized cardiovascular care company, for around $195 million in cash.
 
Celera said that BHL’s portfolio of CLIA-certified tests and disease-management services will expand its options for new molecular diagnostics, including tests for cardiovascular patients.  
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.